Studies have confirmed that early diagnosis and treatment of wind-like disease can not only maintain long-term control or remission of the disease, but can also lead to drug withdrawal. In the last decade, a large number of biologics (mainly tumor necrosis factor inhibitors) have been used in the treatment of P. aeruginosa. Randomized controlled trials have shown that early application of biologics improves outcomes and effectively delays joint destruction, and biologics manufacturers have made efforts to promote early application of biologics in patients with achalasia. However, the best option for the early treatment of P. aeruginosa has not yet been determined. A cost effective research paper comparing three drug regimens for the treatment of very early stages (≤3 months after the onset of symptoms) of P. aeruginosa was published in the November 3, 2009 issue of the American Journal of the Archives of Internal Medicine. The three treatment regimens were a symptomatic or “pyramid” regimen (i.e., NSAIDs, patient education, pain relief, and low-dose glucocorticoids first, with a course-improving drug at 1 year for those who failed), an early course-improving traditional drug (methotrexate) regimen, and an early methotrexate and biologic combination regimen. The primary endpoint was the number of patients who were treated with methotrexate. The primary endpoint was the cost per quality of life year. The results found that the early intervention regimen was significantly better than the pyramidal regimen in slowing joint erosion and functional impairment and was effective in saving long-term costs. When the cost of early medication was taken into account, the cost per quality of life year for the early course improvement drug regimen was $4,849 compared to the pyramid regimen, while the early biologic regimen was significantly more expensive. At the same time, early course improvement drug regimens maximize the effect of early treatment and are the most cost-effective. If the drug cost of biologics can decrease, the cost effectiveness of early biologic regimens will increase and the risk of patient death will decrease. This study concludes that very early application of conventional disease-course improvement drugs for the treatment of wind-like disease is the most cost-effective, while the cost-effectiveness of very early application of biologics is not very clear.